Tevogen Updates Development of AI-Powered EBV-Specific T Cell Therapy

Tevogen Bio Holdings Inc. announced an update on its development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associat...
Home/KnloSights/Clinical Trial Updates/Tevogen Updates Development of AI-Powered EBV-Specific T Cell Therapy